Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients

被引:0
|
作者
Elmer, GW
McFarland, LV
Surawicz, CM
Danko, L
Greenberg, RN
机构
[1] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA
[2] Biocodex Inc, Seattle, WA USA
[3] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA
[4] Univ Kentucky, Dept Med, Div Infect Dis, Lexington, KY 40506 USA
[5] Lexington Vet Affairs Med Ctr, Lexington, KY USA
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Despite recent interest in therapeutic microorganisms taken orally, little is known about the pharmacodynamics of these agents in a target population of patients with disease. The present study reports the stool concentrations of Saccharomyces boulardii in a patient population with Clostridium difficile disease (CDD) and correlates stool concentrations with efficacy. Methods: Patients with recurrent CDD all received a 10-day standard antibiotic regimen together with 28 days of S. boulardii or placebo. Stool samples were collected from patients at various time points and assayed for S. boulardii. Results: The mean concentration of S. boulardii of patients who recurred was 2.5 x 10(4) CFU/g compared to 1 x 10(6) CFU/g in patients that did not recur (P=0.02). Patients with low yeast concentrations in their stools (< 10(4)/g) recurred more often (14/15, 93%) compared with patients with higher levels (19/35, 54%, P=0.007). Clearance of S. boulardii was rapid; only 4% had positive stools 3 days after stopping dosing. Conclusions: After chronic dosing of S. boulardii, patients with low stool concentrations had a higher likelihood of recurrence of CDD. Stool concentrations were also lower during periods of diarrhoea. These results show the importance of characterizing the dynamics of a therapeutic microorganism in patients with disease, as kinetic studies in healthy volunteers may not give a true reflection of the disturbed microecology in the disease state.
引用
收藏
页码:1663 / 1668
页数:6
相关论文
共 50 条
  • [21] Recurrent Clostridium difficile Infection in Patients With Chronic Kidney Disease
    Abdelfatah, Mohamed
    Nijim, Ala
    Nayfe, Rabih
    Enriquez, Kathleen
    Khouri, Jamil
    El Zoghbi, Maysaa
    Watkins, Richard
    Kandil, Hossam
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S201 - S202
  • [22] Recurrent Clostridium difficile colitis in inflammatory bowel disease patients
    Issa, Mazen
    Weber, Lydia R.
    Kanaa, Yasmin
    Emmons, Jeanne
    Skaros, Susan
    Knox, Joshua F.
    Otterson, Mary F.
    Binion, David G.
    GASTROENTEROLOGY, 2007, 132 (04) : A660 - A660
  • [23] Use of prophylactic Saccharomyces boulardii to prevent Clostridium difficile infection in hospitalized patients: a controlled prospective intervention study
    Carstensen, Jeppe West
    Chehri, Mahtab
    Schonning, Kristian
    Rasmussen, Steen Christian
    Anhoj, Jacob
    Godtfredsen, Nina Skavlan
    Andersen, Christian Ostergaard
    Petersen, Andreas Munk
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (08) : 1431 - 1439
  • [24] RANDOMIZED PLACEBO-CONTROLLED TRIAL OF SACCHAROMYCES-BOULARDII IN COMBINATION WITH STANDARD ANTIBIOTICS FOR CLOSTRIDIUM-DIFFICILE DISEASE
    MCFARLAND, LV
    SURAWICZ, CM
    GREENBERG, RN
    FEKETY, R
    ELMER, GW
    MOYER, KA
    MELCHER, SA
    BOWEN, KE
    COX, JL
    NOORANI, Z
    HARRINGTON, G
    RUBIN, M
    GREENWALD, D
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (24): : 1913 - 1918
  • [25] Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa
    Castagliuolo, I
    Riegler, MF
    Valenick, L
    LaMont, JT
    Pothoulakis, C
    INFECTION AND IMMUNITY, 1999, 67 (01) : 302 - 307
  • [26] Probiotics for Clostridium difficile-associated diarrhea:: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii
    Segarra-Newnham, Marisel
    ANNALS OF PHARMACOTHERAPY, 2007, 41 (7-8) : 1212 - 1221
  • [27] Yeast serine protease from Saccharomyces boulardii protects against Clostridium difficile toxin A.
    Castagliuolo, I
    Qiu, BS
    LaMont, JT
    Pothoulakis, C
    GASTROENTEROLOGY, 1996, 110 (04) : A879 - A879
  • [28] RECURRENT CLOSTRIDIUM-DIFFICILE INFECTION IN A PATIENT WITH SELECTIVE IGG1 DEFICIENCY TREATED WITH INTRAVENOUS IMMUNE GLOBULIN AND SACCHAROMYCES-BOULARDII
    HASSETT, J
    MEYERS, S
    MCFARLAND, L
    MULLIGAN, ME
    CLINICAL INFECTIOUS DISEASES, 1995, 20 : S266 - S268
  • [29] SACCHAROMYCES-BOULARDII INHIBITS CLOSTRIDIUM-DIFFICILE TOXIN-A BINDING AND ENTEROTOXICITY IN RAT ILEUM
    POTHOULAKIS, C
    KELLY, CP
    JOSHI, MA
    GAO, N
    OKEANE, CJ
    CASTAGLIUOLO, I
    LAMONT, JT
    GASTROENTEROLOGY, 1993, 104 (04) : 1108 - 1115
  • [30] PURIFIED SACCHAROMYCES-BOULARDII PROTEASE INHIBITS CLOSTRIDIUM-DIFFICILE TOXIN A EFFECTS IN RAT ILEUM
    CASTAGLIUOLO, I
    LAMONT, JT
    BAKER, C
    GUZMAN, DD
    NIKULASSON, ST
    POTHOULAKIS, C
    GASTROENTEROLOGY, 1995, 108 (04) : A792 - A792